Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00605319 · ClinicalTrials.gov registry record · Phase 4
An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia
A Phase 4 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
NCT00605319 is a Phase 4 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 17 participants.
The verdict
NCT00605319, a Phase 4 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
Study Summary
The subjects who have symptoms of overactive bladder (many trips to the bathroom, and urgency with or without the inability to hold your urine until you get to the toilet) are invited to participate in this research study.
Interventions
- DRUG Toviaz (Fesoterodine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00605319
The ClinicalTrials.gov registry entry for NCT00605319 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Toviaz (Fesoterodine) is the first listed.
NCT00605319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00605319 about?
NCT00605319 is a clinical study titled "An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia". The subjects who have symptoms of overactive bladder (many trips to the bathroom, and urgency with or without the inability to hold your urine until you get to the toilet) are invited to participate in this research study.
What is the current status of trial NCT00605319?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2010-01. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00605319?
The interventions under investigation include: Toviaz (Fesoterodine) (DRUG).
Who is sponsoring clinical trial NCT00605319?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.